Pfizer, Repligen unite to develop spinal muscular atrophy drugs

Pfizer and Repligen will develop the latter's spinal muscular atrophy program including experimental SMA drug RG3039 as part of a licensing deal. RG3039, which was licensed from patient advocacy group Families of SMA, holds orphan-drug status in the U.S. and Europe as well as fast-track designation in the U.S. Repligen will receive $5 million upfront and as much as $65 million in milestone fees plus royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations